Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy
BackgroundThis study aimed to investigate the prognostic value of pretreatment lactate dehydrogenase to albumin ratio (LAR) in advanced non-small cell lung cancer (NSCLC) patients treated with first-line programmed cell death protein 1 (PD-1) checkpoint inhibitors and chemotherapy.MethodsA retrospec...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1473962/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823856549052809216 |
|---|---|
| author | Meifeng Luo Huiting Wei Moqin Qiu Cuiyun Su Ruiling Ning Shaozhang Zhou |
| author_facet | Meifeng Luo Huiting Wei Moqin Qiu Cuiyun Su Ruiling Ning Shaozhang Zhou |
| author_sort | Meifeng Luo |
| collection | DOAJ |
| description | BackgroundThis study aimed to investigate the prognostic value of pretreatment lactate dehydrogenase to albumin ratio (LAR) in advanced non-small cell lung cancer (NSCLC) patients treated with first-line programmed cell death protein 1 (PD-1) checkpoint inhibitors and chemotherapy.MethodsA retrospective cohort study was conducted on advanced NSCLC patients treated with first-line PD-1 checkpoint inhibitors plus chemotherapy at Guangxi Medical University Cancer Hospital. The receiver operating characteristic (ROC) analysis determined the optimal LAR cutoff values for prediction. Univariate and multivariate analyses identified independent prognostic factors, and survival curves were estimated using the Kaplan-Meier method. Subgroup analysis evaluated the association between high LAR and disease progression and death risk.ResultsA total of 210 patients were enrolled, with a mean age of 58.56 ± 10.61 years and a male proportion of approximately 79.05%. ROC analysis found the optimal LAR cutoff value was 5.0, resulting in a sensitivity of 78.87% and a specificity of 44.6% (area under the ROC curve 0.622; P = 0.001). Multivariate analysis revealed a significant positive association between LAR and overall survival (OS) after adjusting for confounders (HR = 2.22, 95% CI = 1.25-3.96, P = 0.007). Subgroup analysis confirmed the relationship between high LAR and the risk of disease progression and death across all patient subgroups.ConclusionsPretreatment LAR may be a potential independent prognostic marker for advanced NSCLC patients receiving PD-1 checkpoint inhibitors plus chemotherapy. A large-scale, prospective study is necessary to confirm these findings. |
| format | Article |
| id | doaj-art-fa4011984f3540d4a134e2b893b3386a |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-fa4011984f3540d4a134e2b893b3386a2025-02-12T07:26:34ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.14739621473962Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapyMeifeng LuoHuiting WeiMoqin QiuCuiyun SuRuiling NingShaozhang ZhouBackgroundThis study aimed to investigate the prognostic value of pretreatment lactate dehydrogenase to albumin ratio (LAR) in advanced non-small cell lung cancer (NSCLC) patients treated with first-line programmed cell death protein 1 (PD-1) checkpoint inhibitors and chemotherapy.MethodsA retrospective cohort study was conducted on advanced NSCLC patients treated with first-line PD-1 checkpoint inhibitors plus chemotherapy at Guangxi Medical University Cancer Hospital. The receiver operating characteristic (ROC) analysis determined the optimal LAR cutoff values for prediction. Univariate and multivariate analyses identified independent prognostic factors, and survival curves were estimated using the Kaplan-Meier method. Subgroup analysis evaluated the association between high LAR and disease progression and death risk.ResultsA total of 210 patients were enrolled, with a mean age of 58.56 ± 10.61 years and a male proportion of approximately 79.05%. ROC analysis found the optimal LAR cutoff value was 5.0, resulting in a sensitivity of 78.87% and a specificity of 44.6% (area under the ROC curve 0.622; P = 0.001). Multivariate analysis revealed a significant positive association between LAR and overall survival (OS) after adjusting for confounders (HR = 2.22, 95% CI = 1.25-3.96, P = 0.007). Subgroup analysis confirmed the relationship between high LAR and the risk of disease progression and death across all patient subgroups.ConclusionsPretreatment LAR may be a potential independent prognostic marker for advanced NSCLC patients receiving PD-1 checkpoint inhibitors plus chemotherapy. A large-scale, prospective study is necessary to confirm these findings.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1473962/fullLARprognosisnon-small cell lung cancerPD-1 checkpoint inhibitorschemotherapy |
| spellingShingle | Meifeng Luo Huiting Wei Moqin Qiu Cuiyun Su Ruiling Ning Shaozhang Zhou Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy Frontiers in Immunology LAR prognosis non-small cell lung cancer PD-1 checkpoint inhibitors chemotherapy |
| title | Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy |
| title_full | Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy |
| title_fullStr | Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy |
| title_full_unstemmed | Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy |
| title_short | Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy |
| title_sort | prognostic value of the lactate dehydrogenase to albumin ratio in advanced non small cell lung cancer patients treated with the first line pd 1 checkpoint inhibitors combined with chemotherapy |
| topic | LAR prognosis non-small cell lung cancer PD-1 checkpoint inhibitors chemotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1473962/full |
| work_keys_str_mv | AT meifengluo prognosticvalueofthelactatedehydrogenasetoalbuminratioinadvancednonsmallcelllungcancerpatientstreatedwiththefirstlinepd1checkpointinhibitorscombinedwithchemotherapy AT huitingwei prognosticvalueofthelactatedehydrogenasetoalbuminratioinadvancednonsmallcelllungcancerpatientstreatedwiththefirstlinepd1checkpointinhibitorscombinedwithchemotherapy AT moqinqiu prognosticvalueofthelactatedehydrogenasetoalbuminratioinadvancednonsmallcelllungcancerpatientstreatedwiththefirstlinepd1checkpointinhibitorscombinedwithchemotherapy AT cuiyunsu prognosticvalueofthelactatedehydrogenasetoalbuminratioinadvancednonsmallcelllungcancerpatientstreatedwiththefirstlinepd1checkpointinhibitorscombinedwithchemotherapy AT ruilingning prognosticvalueofthelactatedehydrogenasetoalbuminratioinadvancednonsmallcelllungcancerpatientstreatedwiththefirstlinepd1checkpointinhibitorscombinedwithchemotherapy AT shaozhangzhou prognosticvalueofthelactatedehydrogenasetoalbuminratioinadvancednonsmallcelllungcancerpatientstreatedwiththefirstlinepd1checkpointinhibitorscombinedwithchemotherapy |